

## INSIDE THIS ISSUE

- [Editor's Choice](#): Changes in Dual Modality Treatment (Chemoradiotherapy) Protocols
  - [Cancer Drug Manual](#): **New**: Paclitaxel, albumin-bound nanoparticle (nab) (ABRAXANE®); **Complete Revision**: Porfimer, Streptozocin  
**Chemotherapy Preparation and Stability Chart**: New Products (nab-Paclitaxel, Alemtuzumab Vial), Methotrexate for Intrathecal Use (Vial Size Revised), Extended Expiry (Docetaxel, Etoposide), Routine Update (Porfimer, Streptozocin), Reminder to Record Time of Vial Puncture, Clarifications of Final Concentrations and Protection from Light;  
**Patient Handouts in Action**
  - **Frequently Asked Questions**: Protective Reassignment of Staff Duties for Hazardous Drugs
  - [List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts](#): **New**: GOOVIPPC
- Revised:** BRAJACT, BRAVCLOD, BRAVPAM, CNAJTMZ (CNAJZRT), GIEFUP (GIEFUPRT), GIENDO2, GIFUA (GIFUART), GIFUC, GIFUR (GIFURRT), GIFURC (GIFURCRT), GIGAI (GIGAIRT), GOCXRADC (GOCXCRT), GOSMCC2 (GOSMCCRT), GOTDLR, GUAVPG, GUBPW (GUBPWRT), GUBRADC (GUBPRT), GUEP, GUFUP (GUFUPRT), GUSCPE (GUSCPERT), HNCMT (HNCAFRT), HNCMT2 (HNLAPRT), HNFUA (HNFURT), HNFUP (HNPRT), HNRADC (HNLANPRT), HNRAMI (HNAMIRT)
- [Continuing Education](#) – Canadian Association of Nurses in Oncology Conference, National Oncology Pharmacy Symposium, BC Cancer Agency Annual Cancer Conference
  - [Website Resources](#)

[IN TOUCH](#) phone list is provided if additional information is needed.

## EDITOR'S CHOICE

### CHANGES IN DUAL MODALITY TREATMENT (CHEMORADIO THERAPY) PROTOCOLS

There have recently been two critical incidents related to patients who are receiving concurrent dual modality treatment (chemoradiotherapy). In these combined treatment protocols, the timing of chemotherapy and radiation therapy is crucial to the success of the treatment. Fundamental to both of these instances was a lack of coordination in the timing of the chemotherapy and radiation therapy.

To help identify which protocols are dual modality and hence reduce the confusion related to timing of therapies, the following changes are being implemented to chemoradiotherapy protocols and provincial pre-printed orders (PPPOs):

1. *Protocol code*: 'RT' will be placed at the end of each protocol code.
2. *Protocol titles*: will include a description of both chemotherapy and radiation therapy. This ensures that the whole intent of treatment is captured (i.e., chemotherapy and radiation therapy) and helps members of the treating team understand the entire therapeutic picture required for the patient.

Also see **List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts**.

**Porfimer Monograph and Patient Handout** have been completely revised and updated. Expert review was provided by Dr. Stephen Lam (Lung Tumour Group). Highlighted monograph changes include:

- updated Uses section
- additions to the Special Precautions section and Pharmacokinetics table
- expanded Side Effect table, including many side effects limited to the tumour site or organ being treated

Handout changes include:

- added statement regarding patient or family history of porphyria
- reformatting to include the management of photosensitivity within the Side Effects table
- the inclusion of management details for several potential side effects including irritation, fever, insomnia, constipation and diarrhea

**Streptozocin Monograph and Patient Handout** have been completely revised and updated. Expert review was provided by Dr. Sharlene Gill (Gastrointestinal Tumour Group). Monograph changes include additions to the special precautions section and side effects table.

**Paclitaxel, albumin-bound nanoparticle (nab) (ABRAXANE®) Interim Monograph** has been developed. Interim monographs contain basic drug information, as well as preparation and administration instructions.

**Chemotherapy Preparation and Stability Chart** has been revised with the following:

- New products: nab-paclitaxel (ABRAXANE®), alemtuzumab supplied in vials
- Extended expiry: docetaxel, etoposide (Novopharm)
- Methotrexate for intrathecal use: vial size changed to 50 mg/2 mL per BC Cancer Agency Pharmacy policy
- Routine review and updating: porfimer and streptozocin
- Drugs with short expiry: addition of reminder to record time of initial puncture of vials
  - carmustine
  - mechlorethamine
  - porfimer
  - cytarbine
  - medroxyprogesterone
  - thiotepa
  - doxorubicin
  - octreotide
- Drugs with concentration-dependent stability: clarifications of final concentrations
  - carboplatin
  - fluorouracil
  - fludarabine
  - leucovorin
- Drugs requiring protection from light: clarification of caution needed for final products
  - cytarabine syringe
  - daunorubicin
  - dacarbazine
  - porfimer

**Patient Handouts in Action** Have you ever wondered which side effects are included in Cancer Drug Manual patient handouts, or noticed that important information tends to appear on the last page of the handout? Are you unsure how to use the handouts to counsel patients effectively?

You may be interested to know that the **table** generally lists side effect with **>10% incidence**. Obviously, many drugs have other side effects with lower incidence, but which have recognizable symptoms and require medical treatment. These side effects only appear in the Check with Your Doctor section. When counselling patients, you may want to progress through the handout sequentially:

- Review the bullet points on the first page fairly quickly. Explain these as “common sense things”: the names of the drug, what it is, how to use it, and how to store it.
- Spend the bulk of your time reviewing the Side Effects table. This is what most patients will remember and refer back to. Explain this as “important side effects and what to do about them.”
- Review the Check with Your Doctor section in closing. Explain it as “a summary of when to call the doctor.” Reassure patients that some of the side effects listed here are very rare, but require prompt medical attention.

## FREQUENTLY ASKED QUESTIONS: PROTECTIVE REASSIGNMENT OF STAFF DUTIES FOR HAZARDOUS DRUGS

---

Protection of employees handling hazardous drugs (e.g., cytotoxics) requires that appropriate safety procedures are used at all times. A frequently asked question from our colleagues in the Communities Oncology Network is the BCCA policies on protective reassignment of staff members who are pregnant, breast-feeding or attempting to conceive.

### *Overall policies*

Work Safe BC provides the governing regulation, The Occupational Health and Safety (OHS) Regulation. Section 6.49 of the regulation states the following:

1. At any worksite where a worker is occupationally exposed to a cytotoxic drug that is a reproductive toxin, the employer must develop policy and procedures appropriate to the risk, which may include protective reassignment.
2. The policy and procedures must inform workers about the reproductive toxin and identify ways to minimize exposure to the reproductive toxin for a worker who has advised the employer of pregnancy or intent to conceive a child ([www2.worksafebc.com/publications/OHSRegulation/Part6.asp#SectionNumber:6.49](http://www2.worksafebc.com/publications/OHSRegulation/Part6.asp#SectionNumber:6.49))

There are two BCCA Systemic Therapy Policies which address this situation:

- *Cytotoxic Agents, Safe Handling Standards (Policy V-10)* – It is the responsibility of Directors/Managers and Supervisory Staff to make every effort to accommodate requests to change work assignments from staff who are pregnant, breastfeeding or attempting to reproduce.
- *Employee Health: Management of Risks Related to Cytotoxic Agents Policy V-20* – Employees must be fully informed of the potential reproductive hazard. It is the responsibility of the employee handling cytotoxic agents to discuss with their immediate supervisor any desired change in work assignment as a result of their pregnancy, breast-feeding or attempt to reproduce.

### *Application of policies*

The BCCA considers each employee request for protective reassignment on an individual basis, since the circumstances of each situation can be quite varied. All institutions are required to have policies and procedures in place to minimize employee exposure to hazardous drugs at all times. Protective reassignment may not always be feasible due to staffing or other constraints. However, whenever possible, anyone who is pregnant, breastfeeding or actively trying to conceive should not handle hazardous drugs. Individual employers or Health Authorities should be contacted for guidelines relating to the duration of time allowed for the protective reassignment of duties for someone who is attempting to conceive or is breastfeeding.

This and other Frequently Asked Questions can be found by visiting the [Pharmacists Communities Oncology Network Webpage](#).

Submitted by:

Lynne Ferrier, BSc(Pharm), MBA

Pharmacy CON Educator

Fraser Valley Centre – BC Cancer Agency

**LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS**

**BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New and revised protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” approval are prefixed with the letter U.

**NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GOOVIPPC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Primary Treatment of Stage III $\leq$ 1 cm Visible Residual Invasive Epithelial Ovarian Cancer Using Intravenous and Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin

**REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>protocol reactivated with revised eligibility</i>	Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel (TAXOL®)
BRAVCLOD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>osteonecrosis precaution added</i>	Therapy of Bone Metastases in Breast Cancer using Oral Clodronate
BRAVPAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>osteonecrosis precaution added</i>	Treatment of Acute Bone Pain Secondary to Breast Cancer Metastases using Pamidronate or IV Clodronate
CNAJTMZ (new code CNAJZRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Concomitant and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
GIEFUP (new code GIEFUPRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined modality therapy for locally advanced esophageal cancer using 5 Fluorouracil and Cisplatin and Radiation.
GIENDO2	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>dosing adjustment for renal function clarified</i>	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and Doxorubicin
GIFUA (new code GIFUART)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, chemotherapy dosing interval clarified, reference added</i>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Infusional Fluorouracil and Radiation Therapy
GIFUC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title and Eligibility revised to include pancreas carcinoma</i>	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder, Pancreas Carcinoma and Cholangiocarcinoma) and Metastatic Anal using Infusional Fluorouracil and Cisplatin
GIFUR (new code GIFURRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Fluorouracil, Folinic Acid (Leucovorin) and Radiation Therapy

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
<b>GIFURC</b> (new code GIFURCRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Fluorouracil, Folinic Acid (Leucovorin), Capecitabine and Radiation Therapy.
<b>GIGAI</b> (new code GIGAIRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma using Fluorouracil + Folinic Acid (Leucovorin) + Radiation Therapy.
<b>GOCXRADC</b> (new code GOCXCRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, potassium chloride clarified in PPPO</i>	Treatment of High Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent Cisplatin and Radiation
<b>GOSMCC2</b> (new code GOSMCCRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using Paclitaxel, Cisplatin, Etoposide and Carboplatin with Radiation
<b>GOTDLR</b>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Diluent for methotrexate changed</i>	Therapy for Low Risk Gestational Trophoblastic Cancer Using Dactinomycin and Methotrexate
<b>GUAVPG</b>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>alert added for modified Gemcitabine dosing while on Carboplatin</i>	Palliative Therapy for Urothelial Carcinoma Using Cisplatin and Gemcitabine
<b>GUBPW</b> (new code GUBPWRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Treatment of Locally Advanced Bladder Cancer with Weekly Cisplatin and Concurrent Radiation.
<b>GUBRADC</b> (new code GUBPRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Treatment of Locally Advanced Bladder Cancer Using Concurrent Cisplatin with Radiation
<b>GUEP</b>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>typo corrected (magnesium mentioned twice) in Tests, GU Systemic Therapy Contacts revised</i>	Etoposide-Cisplatin Protocol for Germ Cell Cancers
<b>GUFUP</b> (new code GUFUPRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, title revised</i>	Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and Cisplatin with Radiation
<b>GUSCPE</b> (new code GUSCPERT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, title revised</i>	Therapy of Genitourinary Small Cell Tumors using a Platinum and Etoposide with Radiation
<b>HNCMT</b> (new code HNCAFRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck
<b>HNCMT2</b> (new code HNLAPRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Combined Chemotherapy (Cisplatin) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of The Head and Neck
<b>HNFUA</b> (new code HNFURT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Therapy for combined modality therapy for advanced head and neck cancer using Mitomycin C, Fluorouracil and split course radiation therapy

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
<b>HNFUP</b> (new code HNPRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, fluorouracil deleted from protocol</i>	Therapy for advanced head and neck cancer using Cisplatin with Radiation
<b>HNRADC</b> (new code HNLNPRRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed, potassium chloride clarified in PPPO</i>	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation
<b>HNRAMI</b> (new code HNAMIRT)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>protocol code changed</i>	Radioprotection in Head and Neck Radiation using Amifostine

### CONTINUING EDUCATION

**Canadian Association of Nurses in Oncology (CANO) Annual Conference** will be held on **28-31 October, 2007** at the Hyatt Regency Hotel, Vancouver, BC. The theme for this year is *"Using Hearts, Minds and Voices, Oncology Nurses Influencing Cancer Care"*. Conference information and registration forms are available on the CANO website at <http://www.cano-acio.org/>.

**National Oncology Pharmacy Symposium (NOPS) 2007** will be held by the Canadian Association of Pharmacy in Oncology on **26-28 October, 2007** at the Marriott Harbourfront Hotel in Halifax, Nova Scotia. The theme for this year is *"Oncology Pharmacy in Your Community"*. Conference information and registration is available on [www.peopleware.net/index.cfm?siteCode=2431j&](http://www.peopleware.net/index.cfm?siteCode=2431j&).

**BC Cancer Agency Annual Cancer Conference 2007** will be held on **29 November – 1 December**, at the Westin Bayshore Resort & Marina in Vancouver. This critical three-day conference is the BC Cancer Agency's premier professional development, learning and networking event. It is the only Canadian west coast event of its kind, attracting 1000-plus professionals working in the oncology field.

This year's theme, *Innovation and Technology – Bench to Bedside*, creates the framework for our examination of the role of the BC Cancer Agency and its partners in the 'living laboratory' of British Columbia and their endeavours to enhance population-based cancer control outcomes. A highlight of this year's conference is a keynote presentation on November 30 by Dr. Roberta Bondar, a space scientist, neurologist, author, astronaut and Canada's first woman in space.

For a detailed agenda, schedule and registration information, please visit: [www.bccancer.bc.ca/HPI/ACC2007/default](http://www.bccancer.bc.ca/HPI/ACC2007/default)

### WEBSITE RESOURCES

The following are available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under the Health Professionals Info section:

REIMBURSEMENT AND FORMS: BENEFIT DRUG LIST, CLASS II, COMPASSIONATE ACCESS PROGRAM (UNDESIGNATED INDICATION)	<a href="http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms">www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms</a>
CANCER DRUG MANUAL	<a href="http://www.bccancer.bc.ca/cdm">www.bccancer.bc.ca/cdm</a>
CANCER MANAGEMENT GUIDELINES	<a href="http://www.bccancer.bc.ca/CaMgmtGuidelines">www.bccancer.bc.ca/CaMgmtGuidelines</a>
CANCER CHEMOTHERAPY PROTOCOLS	<a href="http://www.bccancer.bc.ca/ChemoProtocols">www.bccancer.bc.ca/ChemoProtocols</a>
CANCER CHEMOTHERAPY PRE-PRINTED ORDERS	<a href="http://www.bccancer.bc.ca/ChemoProtocols">www.bccancer.bc.ca/ChemoProtocols</a> under the index page of each tumour site
SYSTEMIC THERAPY PROGRAM POLICIES	<a href="http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies">www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies</a>
<a href="#">UNCONVENTIONAL CANCER THERAPIES MANUAL</a>	under Patient/Public Info, Unconventional Therapies

## Editorial Review Board

Mário de Lemos, PharmD, MSc(Oncol) (Editor)  
 Sarah Jennings, BSc(Biomed), BScPhm (Assistant Editor)  
 Caroline Lohrisch, MD  
 Johanna Den Duyf, MA  
 Judy Oliver, BScN, MEd

Beth Morrison, MLS  
 Jaya Venkatesh, MHA, CMA  
 Susan Walisser, BSc (Pharm)  
 Gigi Concon (Editorial Assistant)

<b>IN TOUCH</b>	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
BC CANCER AGENCY .....	(604) 877-6000 .....	Toll-Free 1-(800) 663-3333
COMMUNITIES ONCOLOGY NETWORK .....	Ext 2744 .....	<a href="mailto:jvenkate@bccancer.bc.ca">jvenkate@bccancer.bc.ca</a>
EDUCATION RESOURCE NURSE .....	Ext 2638 .....	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
NURSING PROFESSIONAL PRACTICE .....	Ext 2623 .....	<a href="mailto:ilundie@bccancer.bc.ca">ilundie@bccancer.bc.ca</a>
PHARMACY PROFESSIONAL PRACTICE .....	Ext 2247 .....	<a href="mailto:gconcon@bccancer.bc.ca">gconcon@bccancer.bc.ca</a>
PROVINCIAL SYSTEMIC THERAPY PROGRAM .....	Ext 2247 .....	<a href="mailto:gconcon@bccancer.bc.ca">gconcon@bccancer.bc.ca</a>
COMMUNITIES ONCOLOGY NETWORK PHARMACIST .....	Ext 6277 .....	<a href="mailto:lkovacic@bccancer.bc.ca">lkovacic@bccancer.bc.ca</a>
DRUG INFORMATION .....	Ext 6275 .....	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
LIBRARY/CANCER INFORMATION .....	1-(888)-675-8001 .....	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
	Ext 8003	
OSCAR HELP DESK .....	1-(888)-355-0355 .....	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a>
	Fax (604) 708-2051	
COMPASSIONATE ACCESS PROGRAM OFFICE .....	Ext 6277 .....	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a>
(FORMERLY UNDESIGNATED DRUG APPLICATION OFFICE)	Fax (604) 708-2026	
UPDATE EDITOR .....	Ext 2288 .....	<a href="mailto:mdelemos@bccancer.bc.ca">mdelemos@bccancer.bc.ca</a>
CENTRE FOR THE SOUTHERN INTERIOR (CCSI) .....	(250) 712-3900 .....	Toll-Free 1-(888) 563-7773
FRASER VALLEY CENTRE (FVCC) .....	(604) 930-2098 .....	Toll-Free 1-(800) 523-2885
VANCOUVER CENTRE (VCC) .....	(604) 877-6000 .....	Toll-Free 1-(800) 663-3333
VANCOUVER ISLAND CENTRE (VICC) .....	(250) 519-5500 .....	Toll-Free 1-(800) 670-3322